Cargando…
P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429350/ http://dx.doi.org/10.1097/01.HS9.0000846924.89785.04 |
| _version_ | 1784779413449080832 |
|---|---|
| author | Reiter, A. Gotlib, J. Álvarez-Twose, I. Radia, D. H. Luebke, J. Bobbili, P. J. Wang, A. Norregaard, C. Dimitrijević, S. Sullivan, E. Louie-Gao, M. Schwaab, J. Galinsky, I. A. Perkins, C. Sperr, W. R. Sriskandarajah, P. Chin, A. Sendhil, S. R. Duh, M. S. Valent, P. DeAngelo, D. J. |
| author_facet | Reiter, A. Gotlib, J. Álvarez-Twose, I. Radia, D. H. Luebke, J. Bobbili, P. J. Wang, A. Norregaard, C. Dimitrijević, S. Sullivan, E. Louie-Gao, M. Schwaab, J. Galinsky, I. A. Perkins, C. Sperr, W. R. Sriskandarajah, P. Chin, A. Sendhil, S. R. Duh, M. S. Valent, P. DeAngelo, D. J. |
| author_sort | Reiter, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429350 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94293502022-08-31 P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE Reiter, A. Gotlib, J. Álvarez-Twose, I. Radia, D. H. Luebke, J. Bobbili, P. J. Wang, A. Norregaard, C. Dimitrijević, S. Sullivan, E. Louie-Gao, M. Schwaab, J. Galinsky, I. A. Perkins, C. Sperr, W. R. Sriskandarajah, P. Chin, A. Sendhil, S. R. Duh, M. S. Valent, P. DeAngelo, D. J. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429350/ http://dx.doi.org/10.1097/01.HS9.0000846924.89785.04 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Reiter, A. Gotlib, J. Álvarez-Twose, I. Radia, D. H. Luebke, J. Bobbili, P. J. Wang, A. Norregaard, C. Dimitrijević, S. Sullivan, E. Louie-Gao, M. Schwaab, J. Galinsky, I. A. Perkins, C. Sperr, W. R. Sriskandarajah, P. Chin, A. Sendhil, S. R. Duh, M. S. Valent, P. DeAngelo, D. J. P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE |
| title | P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE |
| title_full | P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE |
| title_fullStr | P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE |
| title_full_unstemmed | P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE |
| title_short | P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE |
| title_sort | p1014: overall survival in patients with advanced systemic mastocytosis receiving avapritinib versus midostaurin or cladribine |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429350/ http://dx.doi.org/10.1097/01.HS9.0000846924.89785.04 |
| work_keys_str_mv | AT reitera p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT gotlibj p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT alvareztwosei p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT radiadh p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT luebkej p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT bobbilipj p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT wanga p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT norregaardc p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT dimitrijevics p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT sullivane p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT louiegaom p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT schwaabj p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT galinskyia p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT perkinsc p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT sperrwr p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT sriskandarajahp p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT china p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT sendhilsr p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT duhms p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT valentp p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine AT deangelodj p1014overallsurvivalinpatientswithadvancedsystemicmastocytosisreceivingavapritinibversusmidostaurinorcladribine |